|
US2020297698A1
|
|
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2020167990A1
|
|
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2020146819A1
|
|
Alk5 inhibitors for treating myelodysplastic syndrome
|
|
WO2020118252A1
|
|
Methods for treating castration-resistant and castration- sensitive prostate cancer
|
|
US2020255462A1
|
|
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
WO2020077300A1
|
|
Methods for monitoring tumor lysis syndrome
|
|
WO2019246421A1
|
|
Deuterated alvocidib and alvocidib prodrugs
|
|
WO2019200243A1
|
|
Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer
|
|
WO2019075367A1
|
|
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
|
WO2019055579A1
|
|
Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
|
|
MX2019007332A
|
|
Profiling peptides and methods for sensitivity profiling.
|
|
WO2018094275A1
|
|
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
KR20180034538A
|
|
Concurrent therapy for the treatment of cancer
|
|
WO2016187316A1
|
|
Alvocidib prodrugs having increased bioavailability
|
|
US2016303101A1
|
|
Predicting response to alvocidib by mitochondrial profiling
|
|
WO2016161248A1
|
|
Targeting pim kinases in combination with btk inhibition
|
|
BR112017009552A2
|
|
Methods for Targeting Transcriptional Control in Super Enhancer Regions
|
|
WO2014062838A2
|
|
Pkm2 modulators and methods for their use
|
|
EP2734205A1
|
|
Heterocyclic protein kinase inhibitors
|
